Human isotope fractional absorption studies comparing chelated Magnesium Glycinate vs. Citrate vs. 4% Oxide, CYP2R1/CYP27B1 magnesium-dependent Vitamin D3 activation trials, and Metformin-induced Vitamin B12 holotranscobalamin depletion. Explore 4,327 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
We found that HCE can be more sensitive overall endpoints for detecting treatment benefit as well as found that HCE can support harmonized trial conclusions in the presence of intervention benefits and harms.
NEPA plus OLZ with reduced (6 mg day 1 only) or no DEX is noninferior to standard 4-day DEX for chemotherapy-induced nausea and vomiting prevention in HEC, supporting steroid-sparing strategies particularly relevant in the...
Based on modeling data, inebilizumab had greater long-term efficacy than historical immunosuppressants.
Patients with poorer disease-specific QoL, but not necessarily those with more severe symptoms or higher scores for anxiety and depression, are particularly likely to incur higher annual costs.
No new safety signals were reported.
No clinically relevant differences were observed between the duration or characteristics of hypoglycemic events in efsitora and once-daily treatment groups in the QWINT-2, -3, and -4 trials.
Inclisiran single-drug treatment provided sustained and effective LDL-C reductions with a favorable safety profile in Chinese adults with low/moderate ASCVD risk.
Treatment with abatacept and MTX resulted in significantly greater reduction of biomarkers relevant to RA, and high baseline IL-10 levels predicted better treatment response with abatacept and MTX versus placebo and MTX across...
No identified covariates were clinically relevant.
NTI164 significantly improved core and associated symptoms of ASD compared to placebo.
Early acute eGFR changes were common and adversely prognostic in patients with HFpEF.
Triple combination therapy with Val/Aml/CTD demonstrated superior blood pressure reduction and a favorable safety profile in patients with essential high blood pressure inadequately controlled on Val/Aml dual therapy,...
The purpose of this paper is to evaluate patient characteristics and treatment outcomes in patients with nonradiographic axial spondyloarthritis (nr-axSpA) eligible for a clinical trial based on the 2009 established Assessment...
Sublingual minoxidil was an effective and well tolerated option in this population for promoting hair growth in trans people receiving testosterone.
The primary endpoint is progression-free survival (PFS), by blinded independent central review (BICR).
This prematurely ended study failed to confirm REX-001's efficacy for ulcer healing.
Prehospital magnesium followed by alteplase was feasible and safe but did not demonstrate a significant overall clinical benefit.
Simulations incorporating PK/PD variability indicated that 45 mg/kg weekly per current weight maintained full FcRn occupancy in >95% of pregnant individuals, even with dosing delays up to 3 days.
Increasing pulse duration broadened relative muscle recruitment and enhanced distal muscle activation, but posture remained the dominant determinant of overall response magnitude.
Short-term treatment with daridorexant does not impair sleep-disordered breathing and may improve sleep in patients with severe OSA.
CNS symptom burden was associated with suboptimal CINV control, while 5 mg of olanzapine maintained superior antiemetic efficacy across CNS symptom strata.
Of 881 patients, complete occlusion was present in 218 in the control and 216 in the tenecteplase arm, near occlusion in 102 and 92 and no visible occlusion in 130 and 123, respectively.
Conclusions: Adjunctive lumateperone 42 mg did not worsen sexual functioning and was not associated with treatment-related sexual dysfunction in patients with MDD with inadequate response to ADT.
Mepolizumab improved exacerbation-related outcomes in patients with COPD and type 2 inflammation, characterized by both consistently and intermittently elevated BEC.
ADA induction had no apparent impact on safety.
This subanalysis of the SELECT-EARLY Japanese population corroborates findings from the global study population on the long-term clinical real-world benefits and safety of upadacitinib.
Exploratory outcomes include the incidence of depressive and anxiety symptoms at 90 days.
Results confirm watch-and-wait as standard of care for patients with early-stage CLL, especially in high-risk CLL characterized by del(17p) and/or mutated TP53.
S0777's success underscores the importance of pre-specified interim monitoring plans and cautions against premature trial termination.
40Gy/15fx for locoregional radiotherapy of BC did not result in more lymphedema compared with 50Gy/25fx.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
